Health Extenders Overview and Outlook

Brownstein Hyatt Farber Schreck

Brownstein Hyatt Farber Schreck

On Friday, Sept. 27, President Trump signed a continuing resolution (CR) to fund the government at current levels until Nov. 21. This extended funding for the 20 health care programs that were set to expire at the end of the fiscal year, Sept. 30. If Congress fails to reach a deal before the new Nov. 21 deadline, which is expected, they will pass another CR to continue funding through Dec. 13. This article describes the health programs that are set to expire, the funding cuts that are scheduled to go into effect, and legislation that Congress will consider to pay for these health “extenders.”


Due to the political nature of several provisions related to gun control, abortion and border wall funding, and disagreements between Democrats and Republicans on top-line spending levels, Senate Appropriations Committee Chair Richard Shelby (R-AL) has suggested that Congress may pass a full-year CR. This would maintain current funding levels for both the programs originally set to expire Sept. 30 and the five additional programs set to expire Dec. 31 through the next year.

In discussing health care “extenders,” we are referring to the extension of time-limited public health programs that will lapse once a statutory deadline is reached, unless there is further legislative action. These include programs for community health centers, safety net hospitals, juvenile diabetes programs, mental health and addiction treatment facilities, and several others, which will be discussed in more detail below. The programs are all related to Medicare, Medicaid, the Children’s Health Insurance Program (CHIP), and private health insurance programs and activities, or health care-related provisions that were enacted in the Patient Protection and Affordable Care Act (ACA; P.L. 111-148) or last extended under the Bipartisan Budget Act of 2018 (BBA 2018; P.L. 115-123).

Though many of these programs enjoy bipartisan support, there are concerns about what measures Congress might pass to pay for the cost of these programs, estimated from $20 billion‒$40 billion, depending on how long the programs are extended (2 years versus 5 years).

Expiring Programs

Programs Expiring Nov. 21:

Health Care-Related Program



Cost to Extend


Protections for Recipients of Home and Community-Based Services against Spouse Impoverishment

SSA §1924

42 U.S.C. §1296r-5

No cost estimate


Additional Medicaid Funding for the Territories

SSA §1108

42 U.S.C. §1308

FY2020 DHS allotment ratio to $300 million, subsequent years subject to an increase


Money Follows the Person (MFP) Rebalancing Demonstration Grant

DRA, §6071(g)(2)

Affordable Care Act, §2403(a)

$254.5 million for the remainder of 2019 (not scheduled to receive any new funding after this year)


Outreach and Assistance for Low-Income Programs

MIPPA §119

42 U.S.C. §1395b-3 note

$37.5 million annually (SHIPs, $13 million; AAAs, $7.5 million; ADRCs, $5 million; contract

with the National Center for Benefits and Outreach Enrollment, $12 million)


Temporary Extension of LTCH Site Neutral Payment Policy Transition Period

SSA §1886(m)(6)(B)(i)

42 U.S.C.


No cost estimate


Temporary Exception for Certain Spinal Cord Conditions from Application of the Medicare LTCH Site Neutral Payment for Certain LTCHs

SSA §1886(m)(6)(F) 42 U.S.C. §1395ww(m)(6)(F)

No cost estimate


Funding for Implementation of Section 101 of MACRA

MACRA § 101(c)(3))

No cost estimate


Priorities and Funding for Measure Development

SSA §1848(s) 42 U.S.C. §1395w-4(s)

Funds appropriated prior to FY2020 are available for obligation through the end of FY2022 ($15 million/year from FY2015 through FY2019)


Contract with a Consensus-Based Entity Regarding Performance Measurement

SSA §1890(d) 42 U.S.C. §1395aaa

Funds appropriated prior to FY2020 are available for obligation until expended ($7.5 million/year from FY2018 and FY2019)


Quality Measure Selection

SSA §1890A 42 U.S.C. §1395aaa-1

Funds appropriated prior to FY2020 are available for obligation until expended ($7.5 million/year from FY2018 and FY2019)


Patient-Centered Outcomes Research Trust Fund

IRC §9511 and §§4375- 4377, SSA §1183); 26 U.S.C. §9511; 26 U.S.C. §§4375-4377; 42 U.S.C. §1320e-2

$150 million/year if programs are funded through FY2026


Family-to-Family Health Information Centers

SSA §501(c) 42 U.S.C. §701(c)(1)(A)(iii)

$6 million/year if programs are funded through FY2024


Sexual Risk Avoidance Education Program

SSA §501 42 U.S.C. §710

No cost estimate


Personal Responsibility Education Program

SSA §513 42 U.S.C. §713(f)

$75 million/year if programs are funded through FY2024


Pregnancy Assistance Fund

ACA §10212 42 U.S.C. §18201-18204

$25 million/year if programs are funded through FY2024


Teaching Health Centers

PHSA §340H 42 U.S.C. §256h

$126.6 million/year if programs are funded through FY2024


Community Health Centers Fund

PHSA §330 42 U.S.C. §254b-2(b)(1)

$4 billion/year if programs are funded through FY2024


Special Diabetes Programs

PHSA §330B and §330C 42 U.S.C. §254c-2(b) and §254c-3(b)

$200 million/year if programs are funded through FY2024


National Health Service Corps Appropriations

PHSA §338H 42 U.S.C. §254b-2(b)(2)

$385 million/year if programs are funded through FY2024


Teaching Health Centers

PHSA §340H 42 U.S.C. §256h

$126.5 million/year if programs are funded through FY2024

Programs Expiring Dec. 31:

Health Care-Related Program



Cost to Extend


Floor on Work Geographic Practice Cost Indices

SSA §1848(e)(1) 42 U.S.C. §1395w4(e)(1)(E)

$955 million over 2018-2022 period if programs are funded through 2022


Transitional Payment Rules for Certain Radiation Therapy Services

SSA §1848 42 U.S.C. 1395w-4(b)(11)

No cost estimate

Private Health Insurance

Health Coverage Tax Credit

IRC §35 26 U.S.C. §35

No cost estimate

Private Health Insurance

Annual Fee on Health Insurance Providers Goes into Effect on Jan. 1

ACA §9010

Raises $161 billion over 2019-2028 period

(-$13 billion in 2018, reaching -$22 billion by 2028)

Private Health Insurance

Excise Tax on Medical Device Manufacturers

26 U.S.C. §4191

Raises $19.6 billion over 2017-2026 period if tax goes into effect

Medicaid Disproportionate Share Hospital (DSH) Cuts

The Medicaid DSH program is designed to give safety-net hospitals, which serve a large share of low-income and uninsured patients, more financial flexibility by requiring Medicaid to make payments to qualifying hospitals using both state and federal funds. Under the Affordable Care Act (ACA), Congress would have reduced federal DSH allotments beginning in 2014 to account for the anticipated decrease in uncompensated care; however, several pieces of legislation have been enacted since 2010 that have delayed the reduction schedule.

On Sept. 23, the Centers for Medicare and Medicaid Services (CMS) published a final rule for calculating $4 billion in state Medicaid DSH cuts for FY 2020 and $8 billion each subsequent year through 2025. These cuts were set to go into effect on Oct. 1, but were delayed to Nov. 21 through the CR signed on Sept. 27.

Members of Congress on both sides of the aisle are seeking a fix for DSH cuts, though they have disagreed as to whether to repeal the reductions in allotments, continue to delay them, or have the reductions go into effect with changes to the formula for reductions. While Republicans do not support the DSH cuts imposed by the ACA, they would like to see legislation that changes the underlying formula, which they see as flawed. At the end of July, the House Committee on Energy and Commerce passed Rep. Tom O’Halleran’s (D-AZ) bipartisan Reauthorizing and Extending America’s Community Health (REACH) Act (H.R. 2328), which would eliminate the scheduled reductions to Medicaid DSH funding for FY 2020 and FY 2021, and reduce the cuts by half in FY 2022, for a total of $16 billion in relief. The legislation would also provide new funding to community health centers, the National Health Service Corps, and several other expiring health care programs, and protect patients from surprise medical bills. The Senate Finance Committee has not agreed on how to proceed on DSH cuts or other health extenders, and given the short time frame, may agree to the House version of the bill.

Potential Offsets

Before the next round of funding expires, Congress will need to determine how to pay for the health care extenders and a repeal or further delay of the DSH cuts. Members have been considering several different options for reducing health costs, including through legislation addressing surprise medical bills and prescription drug prices. The following pieces of legislation are being explored as potential pay-fors:

  1. H.R. 2375 / S. 64 – Preserve Access to Affordable Generics and Biosimilars Act: This bill would prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic in the market, or “pay-for-delay.” While this bill has not yet been scored by the Congressional Budget Office (CBO), the office unofficially estimated that a similar bill, the Biosimilars Competition Act of 2018, would save an estimated $100 million from 2019‒2028.
  2. H.R. 965 / S. 340 – Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019: This bill would allow a biosimilar or generic developer to bring a civil action against an innovator drug company if the latter refuses to make enough samples of a product available for testing. It would also explicitly empower the Food and Drug Administration (FDA) to approve alternative Risk Evaluation and Mitigation Strategy (REMS) programs if a generic or biosimilar developer and the innovator company are unable to arrive at a single shared system. In 2018, the CBO estimated that implementing the legislation would reduce spending by $3.3 billion over the 2019-2028 period and increase revenues by $600 million over the same period.
  3. H.R. 2296 / S. 1391 – Fair Accountability and Innovative Research (FAIR) Drug Pricing Act of 2019: This bill would require drug manufacturers to disclose and provide more information about planned drug price increases, including research and development costs. The Department of Health and Human Services (HHS) would make all of the information from these reports publicly available within 30 days in an understandable online format, and submit an annual report to Congress summarizing the submitted information. CBO has not scored this proposal, but by reducing drug prices, the legislation would likely reduce direct health care spending.
  4. Prescription Drug Cost Reduction Act (PDPRA) of 2019 (Senate Finance Committee package): This package would raise the cap on total Medicaid rebate amounts to at least 125% of Average Manufacturer Price (AMP) beginning in FY 2023; bar manufacturer gaming that uses “authorized generics” to lower rebate amounts; require auditing of manufacturer’s pricing and drug product information; extend the Medicaid Drug Rebate Program to certain drugs administered in outpatient hospital settings; prohibit use of “spread pricing” by Pharmacy Benefit Managers (PBMs), address conflicts of interest in administration of the Medicaid drug benefit: improve access to prescription drug data; and facilitate in-depth analysis of the Medicaid Drug Rebate Program. CBO estimates the package would reduce the deficit by over $20 billion over the 2020-2024 period and $100 billion over the 2020-2029 period. Of all the policies in the package, the modification of the maximum rebate amount under the Medicaid drug rebate program is most likely to be used as an offset in an end-of-year package. This policy alone would reduce spending by $1.377 billion over the 2020-2024 period and $12.488 billion over the 2020-2029 period.
  5. S. 1895 – Lower Health Care Costs Act (Senate HELP Package): This bill intends to prevent surprise medical bills, reduce prescription drug prices, improve transparency in health care, invest in public health and improve health information exchange. Specific cost-saving measures include providing timely access to generic drugs and directing drug manufacturers to submit a report justifying planned price increases. According to the CBO, estimated budgetary effects would primarily stem from reduced federal subsidies for health care and health insurance, and increased direct spending for community health centers and other federal health programs. On net, they estimate that enacting the legislation would increase direct spending by about $18.7 billion and increase revenues by $26.2 billion over the 2019-2029 period, for a net decrease in the deficit of $7.6 billion.
  6. H.R. 2328 – Reauthorizing and Extending America’s Community Health (REACH) Act: As discussed above, this bill would reauthorize and extend funding for community health centers through the Community Health Center Fund (CHC Fund), the National Health Service Corps (NHSC), the Teaching Health Center Graduate Medical Education Program, the Special Diabetes Program and the Special Diabetes Program for Indians, Family to Family Health Information Centers, the Personal Responsibility Education Program, the Sexual Risk Avoidance Program, and extensions of certain expiring Medicare programs. It would also reduce scheduled DSH cuts and protect patients from surprise medical billing and reduce payments to some health care providers working in facilities where surprise bills are likely. CBO estimates that enactment of this bill would increase direct spending by about $41.0 billion and increase revenues by $20.9 billion over the 2019-2029 period, for a net increase in the deficit of $20.1 billion.


Though the short-term funding extensions delay the expiration of these programs, community health centers and other groups that depend on the funding are unable to plan ahead due to the uncertainty. Congress is expected to pass another CR to extend funding through mid-December, at which point they will likely pass a full-year CR if a government spending agreement cannot be reached through the appropriations process.

The House and Senate must agree on policies to offset the cost of the health extenders, and it is likely that Congress will pick bipartisan drug bills like CREATES, Pay-for-Delay, and the Medicaid AMP cap. While Congress initially eyed surprise billing legislation as a potential offset, there is broad disagreement over the policy direction for surprise billing legislation, and it is unlikely this legislation will be enacted by the end of the year.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Brownstein Hyatt Farber Schreck | Attorney Advertising

Written by:

Brownstein Hyatt Farber Schreck

Brownstein Hyatt Farber Schreck on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at:

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit
  • New Relic - For more information on New Relic cookies, please visit
  • Google Analytics - For more information on Google Analytics cookies, visit To opt-out of being tracked by Google Analytics across all websites visit This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at:

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.